Jiangsu Hengrui Pharmaceuticals Co., Ltd.SSE: 600276

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA

· Issued by Jiangsu Hengrui Pharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 3 pages · Chinese and English

Summary by 6ix AI

The application is based on a phase three clinical trial that demonstrated significant survival benefits for patients with high-volume metastatic hormone-sensitive prostate cancer. The company emphasizes the need for cautious investment decisions due to the uncertainties involved in the drug approval process.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix

Earlier from Jiangsu Hengrui Pharmaceuticals

Later from Jiangsu Hengrui Pharmaceuticals

All Jiangsu Hengrui Pharmaceuticals news releases